AP -- The future of a partnership between XenoPort Inc. and GlaxoSmithKline PLC appeared to be in doubt Thursday after Glaxo said it may end research on pain treatments. GlaxoSmithKline, one of the world's largest drugmakers, said its neuroscience researchers will focus on inflammatory and degenerative diseases and may stop research into depression and pain drugs. The proposals were part of a cost-saving plan.
